Given the established prognostic value of tau-PET, overperforming other biomarkers [8, 30, 31], the similar ability of visual and semi-quantitative approaches in discriminating cognitive decliners, demonstrated here, is crucial for the implementation of tau-PET in clinical practice. The gene discussed is MAPT; the disease is Mental deterioration.